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Cisplatin is frequently used to treat solid tumors; however,
nephrotoxicity due to its reactive oxygen species-mediated
effect limits its use. We tested the ability of cationized
catalase, a catalase derivative, to inhibit nephrotoxicity in
cisplatin-treated mice. Immunohistochemical analysis
showed that the catalase derivative concentrated in the
kidney more efficiently than native catalase. Repeated
intravenous doses of cationized catalase significantly
decreased cisplatin-induced changes in serum creatinine,
blood urea nitrogen, nitrite/nitrate levels, lactic
dehydrogenase activity, and renal total glutathione and
malondialdehyde contents. In addition, cationized catalase
effectively blunted cisplatin-induced proximal tubule necrosis
but had no significant effect on the cisplatin-induced
inhibition of subcutaneous tumor growth. Repeated doses of
catalase, especially cationized catalase, significantly increased
the survival of cisplatin-treated tumor-bearing mice
preventing cisplatin-induced acute death. Our studies
suggest that catalase and its derivatives inhibit cisplatin-
induced nephrotoxicity, thus improving the efficiency of
cisplatin to treat solid tumors.
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Cisplatin (cis-diammine-dichloroplatinum II) is one of the
most frequently used anticancer agents for the treatment of
solid tumors, including ovarian, testicular, bladder, head and
neck, osteogenic, and uterine cervix carcinomas. Unfortu-
nately, chemotherapy using high-dose cisplatin is often
accompanied by serious side effects that affect the peripheral
neurons and cochlea of the kidney, and these side effects
sometimes lead to termination of the treatment or a
reduction in the dose.1,2 Although the mechanism underlying
cisplatin-induced nephrotoxicity is not yet fully understood,
reactive oxygen species (ROS) have been widely implicated in
the toxicity.3–5 Therefore, various antioxidant enzymes
and antioxidants, including superoxide dismutase, catalase,
glutathione peroxidase, glutathione (GSH), selenium, flavo-
noids, and diethyldithiocarbamates, have been investigated
as compounds able to protect against cisplatin-induced
nephrotoxicity.6–8
Although various ROS could be involved in the ROS-
mediated, cisplatin-induced nephrotoxicity, hydrogen per-
oxide is considered to be an effective target molecule to
inhibit this toxicity. This is because (i) superoxide anion,
which is initially produced, is spontaneously or enzymatically
(by superoxide dismutase) converted to hydrogen peroxide
and (ii) hydrogen peroxide is stable and has a long half-life. If
this is the case, catalase, an enzyme that degrades hydrogen
peroxide into oxygen and water, would be a good candidate
for the inhibition of cisplatin-induced nephrotoxicity.
However, catalase (from bovine liver) is not significantly
distributed to the kidney after intravenous injection9,10 and
this severely limits its therapeutic efficacy against such toxicity.
A series of catalase derivatives with different physico-
chemical properties have been developed in our laboratory,
each of which showed unique tissue distribution character-
istics.10 Our previous studies using these catalase deriva-
tives10–21 clearly indicate that catalase can be highly effective
in inhibiting various ROS-mediated injuries once delivered
to the region of interest. Therefore, a catalase derivative
targeting the kidney would be useful for inhibiting cisplatin-
induced nephrotoxicity.
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Cationic macromolecules have the ability to interact with
the kidneys after entering the blood circulation, as clearly
demonstrated with charged dextrans.22 We have recently
synthesized a cationized derivative of bovine liver catalase,
that is, ethylenediamine (ED)-conjugated catalase (ED-
catalase), and showed that it can protect hepatocytes from
carbon tetrachloride-induced acute liver failure in mice.14
Although ED-catalase does not accumulate to a high degree
in the kidneys because of its extensive uptake by the liver, an
increase in the amount of catalase delivered to the kidney
may be sufficient to inhibit cisplatin-induced nephrotoxicity.
In this study, we first demonstrated that ED-catalase is
more efficiently delivered to the kidneys than catalase. Then,
the effects of ED-catalase on cisplatin-induced nephrotoxicity
were examined in mice by evaluating blood urea nitrogen
(BUN), serum creatinine, nitrite/nitrate levels, lactate dehy-
drogenase (LDH) activity, and the total GSH content and
malondialdehyde (MDA) levels in the kidney. Its effects on
the antitumor activity of cisplatin were also investigated in
tumor-bearing mice.
RESULTS
Renal accumulation of catalase and ED-catalase in mice
Figure 1 shows the immunohistochemical staining of catalase
derivatives in mouse kidneys. Compared with the kidney
section from an untreated mouse (Figure 1a), one from a
mouse receiving an intravenous injection of catalase at a dose
of 1 mg kg1 (40 000 U kg1) showed faint catalase staining in
the proximal tubule regions of the kidney (Figure 1c). To
confirm the renal distribution of catalase, a very high dose of
100 mg kg1 (4 000 000 U kg1) was used, which gave detect-
able signals in the proximal tubules (Figure 1b). On the other
hand, the injection of ED-catalase at the low dose of
1 mg kg1 (18 000 U kg1, 450 U mouse1) resulted in an
intense staining in the same regions (Figure 1d), suggesting
that ED-catalase is more efficiently delivered to the kidney
than unmodified catalase. The total renal catalase activity was
hardly changed by administration of catalase derivatives
(data not shown), because of a very high endogenous catalase
activity in mouse kidneys (14 20072200 U g1 kidney,
52307840 U kidney1).
Single-dose cisplatin-induced nephrotoxicity and its inhibi-
tion by catalase
An intraperitoneal (i.p.) injection of cisplatin at a dose of
20 mg kg1 induced serious injuries in mice, and all mice had
died by 5 days after the injection. Cisplatin also caused
significant weight loss in mice (Figure 2a). In addition, the
BUN and serum creatinine levels were significantly increased by
the injection of cisplatin 2 days after injection (Figure 2b
and c). Administration of catalase (500050 000 U kg1 shot1,
seven injections) significantly reduced the cisplatin-induced
changes in body weight (Figure 2d) and the BUN and serum
creatinine levels (Figure 2e and f) in a dose-dependent manner.
Effect of ED-catalase on single-dose cisplatin-induced ne-
phrotoxicity
Figure 3 shows the effects of catalase and ED-catalase on
the nephrotoxicity induced by a single dose (20 mg kg1, i.p.)
of cisplatin. Both catalase and ED-catalase (10 000 U kg1 shot1,
seven injections) significantly reduced the increase in BUN
(Figure 3a), serum creatinine (Figure 3b), nitrite/nitrate
(Figure 3c) levels, and LDH activity (Figure 3d). The
reduction in the renal total GSH content was inhibited only
by ED-catalase (Po0.05; Figure 3e). The increase in the renal
MDA level was also significantly (Po0.01) inhibited only by
ED-catalase (Figure 3f). For all parameters measured, ED-
catalase produced greater changes than catalase, and the
differences were significant for BUN (Po0.01) and renal
MDA levels (Po0.05). These results indicate that ED-catalase
is more effective than catalase in protecting against
high-dose cisplatin-induced nephrotoxicity, and that the
co-administration of ED-catalase allows an increase in the
cisplatin dose for anticancer therapy. The administration of
cisplatin (20 mg kg1, i.p.) to mice resulted in severe
necrosis in the proximal tubules, with extensive epithelial
vacuolization, swelling, and tubular dilatation (Figure 3h),
which was markedly inhibited in catalase- or ED-catalase-
treated mice (Figure 3i and j). The glomeruli appeared
normal in all the groups studied. The graded histological
changes are summarized in Table 1. Compared with the
saline-treated mice, the catalase- and ED-catalase-treated
groups exhibited much less significant changes. The platinum
content in the kidneys of the saline-treated mice was
1.0170.13 mg kidney1, which was not significantly
(P¼ 0.1) different from that of the ED-catalase-treated mice
(0.7770.18 mg kidney1).
a b
c d
Figure 1 | Immunohistochemical staining of catalase and
ED-catalase in mouse kidneys ( 100 original magnification).
Catalase or ED-conjugated catalase was injected into the tail vein of
mice at a dose of 1 mg kg1. At 30 min after injection, the kidneys
were excised and paraffin-embedded sections were immunostained
for bovine catalase using biotin-conjugated anti-bovine catalase
antibody, followed by incubation with peroxidase-conjugated
antibody. (a) Untreated, (b) high-dose catalase (100 mg kg1),
(c) catalase, and (d) ED-catalase.
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Effect of catalase derivatives on nephrotoxicity induced by
repeated doses of cisplatin
Although ED-catalase was highly effective in inhibiting
cisplatin-induced nephrotoxicity in mice treated with the
high dose of cisplatin, all mice were dead in less than 5 days
irrespective of the treatment. Then, a more moderate regimen
for cisplatin administration was used for the following
experiments. Repeated administration of low-dose cisplatin
(5 mg kg1, three times) also resulted in significant changes
in the parameters investigated (Figure 4). Again, catalase and
ED-catalase (10 000 U kg1 shot1, five injections) signifi-
cantly attenuated the increase in BUN (Figure 4a) and LDH
activity (Figure 4d). Furthermore, ED-catalase was also
effective in inhibiting the elevation in the renal MDA level
(Figure 4f). The platinum contents in the kidneys of
the saline- and the ED-catalase-treated mice were
0.8670.24 and 1.1970.17 mg kidney1, respectively, and
there was no significant difference between them (P¼ 0.07).
Effect of catalase derivatives on the antitumor activity of
cisplatin in tumor-bearing mice
Figure 5a shows the number of B16-BL6/Luc cells in the
subcutaneous tumor tissue 21 days after inoculation.
Repeated doses of low-dose cisplatin (5 mg kg1, three times;
the saline-treated group) were effective in significantly
(Po0.001) reducing the number of tumor cells to less than
10% of those in the untreated group. Co-administration of
catalase or ED-catalase (10 000 U kg1 shot1, five injections)
with cisplatin had little effect on the antitumor activity of
cisplatin. The volume of subcutaneous S180 tumor tissues
was also greatly inhibited by cisplatin (Figure 5b), and no
significant differences were observed between the saline-
treated group and the catalase- or ED-catalase-treated
groups. These results indicate that, although the treatment
with catalase or ED-catalase is effective in reducing cisplatin-
induced nephrotoxicity, neither of them interferes with the
antitumor activity of cisplatin.
Effect of catalase derivatives on the survival of tumor-
bearing mice
Untreated B16-BL6-bearing mice started to die on day 37
after inoculation of tumor cells, and all had died by day 50
(Figure 5c). As reported previously, the repeated doses of
cisplatin (5 mg kg1, three times) resulted in the acute death
of mice, probably due to acute renal failure; 7 out of 12 B16-
BL6-bearing mice, treated with saline, were dead by day 37.
However, some of the animals survived longer than the
untreated mice, and there was no significant difference in the
survival between the untreated and the cisplatin-injected,
saline-treated groups. The administration of catalase or ED-
catalase (10 000 U kg1 shot1, five injections) reduced the
number of mice suffering from cisplatin-induced acute death,
and the survival rates of the cisplatin/catalase- and cisplatin/
ED-catalase-treated mice were significantly (Po0.001) longer
than those of cisplatin/saline-treated mice. Furthermore,
mice receiving ED-catalase lived significantly (Po0.01)
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Figure 2 | Effect of catalase on single-dose cisplatin-induced nephrotoxicity. (a, d) Body weight, (b, e) BUN, and (c, f) serum creatinine
levels in mice. (a–c) Mice received an i.p. injection of saline (vehicle) or cisplatin (20 mg kg1). J, naı¨ve mice; ., saline-injected; K, cisplatin-
injected. Results are expressed as the mean7s.d. of five mice. *Po0.05, ***Po0.001; statistically significant difference compared with the
saline-treated group. (d–f) Effect of catalase on cisplatin-induced changes 72 h after i.p. injection of cisplatin (20 mg kg1). Catalase
(5000–50 000 U kg1 shot1) was injected into the tail vein of mice twice a day, beginning 12 h before the cisplatin injection and continued for
seven doses at 12-h intervals. Mice were euthanized 72 h after the cisplatin injection. UT, untreated; 5–50k, catalase-treated at a dose of
5000–50 000 U kg1 shot1. Results are expressed as the mean7s.d. of five mice. *Po0.05, **Po0.01, ***Po0.001; statistically significant
difference compared with the saline-treated group.
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longer than those given catalase, suggesting that ED-catalase
is more effective than catalase in increasing the lifespan of
B16-BL6-bearing, cisplatin-treated mice. Figure 5e shows the
survival of mice that were alive at 37 days after cisplatin
treatment: 5, 8, and 9 out of 12 mice for the saline-, catalase-,
and ED-catalase-treated groups, respectively. As clearly
demonstrated, ED-catalase significantly (Po0.001) increased
the survival of these mice, suggesting that ED-catalase has
some antitumor activity, in addition to its activity in
preventing cisplatin-induced acute death. Figure 5d and f
shows the survival of S180-bearing mice; similar but slightly
less significant effects of catalase and ED-catalase were
observed.
DISCUSSION
The mechanism of cisplatin-induced subcellular and mole-
cular toxicity is not fully understood, but it has been shown
that cisplatin is capable of binding to several cellular
components, including membrane phospholipids, thiols,
cytoskeletal microfilaments, proteins, RNA, and DNA.23
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Figure 3 | Effect of catalase and ED-catalase on single-dose cisplatin-induced nephrotoxicity. Effect of catalase and ED-catalase on
cisplatin-induced changes in (a) BUN, (b) serum creatinine, (c) nitrite/nitrate levels and (d) LDH activity, (e) renal total GSH content and (f) MDA
level, and (g–j) hematoxylin and eosin staining of kidney sections ( 100 original magnification) 72 h after i.p. injection of cisplatin (20 mg kg1).
Catalase or ED-conjugated catalase (10 000 U kg1 shot1) was injected into the tail vein of mice twice a day, beginning 12 h before the cisplatin
injection and continued for seven doses at 12-h intervals. Mice were euthanized 72 h after the cisplatin injection. UT, untreated; Cat, catalase;
ED-cat, ED-catalase. Results are expressed as the mean7s.d. of 4–6 mice. *Po0.05, **Po0.01, ***Po0.001; statistically significant difference
compared with the saline-treated group. wPo0.05, wwPo0.01; statistically significant difference compared with the catalase-treated group. (g–j)
At 72 h after i.p. injection of cisplatin at a dose of 20 mg kg1, kidneys were removed and 4-mm sections were prepared and stained with
hematoxylin and eosin. (g) Naı¨ve mice; (h–j) for mice receiving cisplatin, (h) saline, (i) catalase or (j) ED-catalase was injected into the tail vein
twice a day, beginning 12 h before the cisplatin injection and continued for seven doses at 12-h intervals, at a dose of 10 000 U kg1.
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In addition, ROS have been implicated as important
mediators of the acute renal failure induced by cisplatin
and other toxic agents, such as gentamicin and cyclosporine
A.24 This study clearly demonstrated that the cisplatin-
induced changes in the serum and renal parameters can be
inhibited by catalase in a dose-dependent manner (Figure 2).
These results suggest that hydrogen peroxide plays a major
role in these toxic effects, which has also been demonstrated
in previous in vitro studies.25,26
In general, high enzymatic activities of catalase and
glutathione peroxidase resulting in degradation of hydrogen
peroxide can be detected in various tissues and cells,
especially in erythrocytes, liver, and kidneys. In this
study, the renal catalase activity was estimated to be
52307840 U kidney1, which was much greater than the
dose of catalase of 450 U mouse1 (18 000 U kg1) or less. In
spite of high endogenous activities of catalase and other
antioxidant enzymes, antioxidant enzymes administered
exogenously are needed to prevent the toxic effects induced
by 100% oxygen9 or by administration of hydrogen
peroxide.20 We have reported that targeted delivery of
catalase to the liver is effective in inhibiting hepatic
ischemia/reperfusion injuries,10–13 carbon tetrachloride-in-
duced acute liver failure,14 and hepatic metastasis of tumor
cells.15–17 In separate investigations, polyethyleneglycol-
conjugated catalase was highly effective in inhibiting
pulmonary metastasis and peritoneal dissemination of tumor
cells.18–21 As the molecular weight of bovine liver catalase
(220 000) is much greater than the threshold of glomerular
filtration of the kidneys (B40 000), catalase derivatives may
distribute to the kidneys, especially to the proximal tubules,
from the capillary side of the epithelial cells in the tubules.
This is similar to the situation of a cationized derivative of
superoxide dismutase; using isolated perfused rat kidneys, we
clearly demonstrated that cationized superoxide dismutase is
taken up by the organ from the capillary side following an
electrostatic interaction.27,28 Renal accumulation of ED-
catalase was clearly demonstrated by immunohistochemistry,
but the total renal catalase activity was not significantly
changed by the administration of ED-catalase because of the
high endogenous catalase activity. However, a significant
reduction in the cisplatin-induced increase in the renal MDA
level, an indicator of oxidative stress, by ED-catalase strongly
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Figure 4 | Effect of catalase and ED-catalase on nephrotoxicity induced by repeated doses of cisplatin. Effect of catalase and ED-catalase
on changes produced by repeated doses of cisplatin involving (a) BUN, (b) serum creatinine, (c) nitrite/nitrate levels and (d) LDH activity, and
(e) the renal total GSH content and (f) MDA level 96 h after the first i.p. injection of cisplatin. Cisplatin was injected at a dose of 5 mg kg1 into
the peritoneal cavity on days 0, 1, and 2 at 24-h intervals. Catalase or ED-conjugated catalase (10 000 U kg1 shot1) was injected into the tail
vein of mice at 12 h before the first injection of cisplatin. The second injection was given to mice immediately after the first injection of
cisplatin, and three additional doses were administered at 24-h intervals. Mice were euthanized 96 h after the first cisplatin injection. UT,
untreated; Cat, catalase; ED-cat, ED-catalase. Results are expressed as the mean7s.d. of 5–8 mice. *Po0.05, **Po0.01; statistically significant
difference compared with the saline-treated group. wPo0.05; statistically significant difference compared with the catalase-treated group.
Table 1 | Semiquantitative analysis of individual histological
grades of kidney damage in mice.
Group Total number analyzed
Histological grade
0 I II III IV
Untreated 4 3 1
Saline, cisplatin 5 2 3
Catalase, cisplatin 5 4 1
ED-catalase, cisplatin 5 5
ED, ethylenediamine.
Mice received intraperitoneal injections of 20 mg kg1 cisplatin. Saline, catalase or
ED-conjugated catalase (10 000 U kg1 shot1) was administered into the tail vein of
mice twice a day, beginning 12 h before the cisplatin injection and this was
continued for seven doses at 12-h intervals. Animals were euthanized 72 h after the
cisplatin injection.
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suggests that an increased catalase activity results in the
inhibition of cisplatin-induced nephrotoxicity by ED-catalase
(Figure 3f). These results clearly indicate that the distribution
or location of catalase, not the total catalase activity, is
important for inhibiting cisplatin-induced nephrotoxicity.
Unmodified catalase showed a marginal, but dose-
dependent effect in inhibiting the cisplatin-induced changes
(Figure 2), although an increase in the dose over
10 000 U kg1 produced hardly any increase in the inhibitory
effects. Hematoxylin and eosin staining of the kidney sections
clearly showed cisplatin-induced necrosis in the proximal
tubules, extensive epithelial vacuolization, swelling, and
tubular dilatation (Figure 3g–j). As ED-catalase has the
ability to distribute to those regions in the kidneys
more efficiently than catalase, as shown in Figure 1, it
would be more effective than catalase in inhibiting the
cisplatin-induced nephrotoxicity; this was most clearly
demonstrated by the reduced numbers of mice dying acutely
(Figure 5c and d).
A very important observation is that catalase derivatives
do not interfere with the antitumor activity of cisplatin.
Furthermore, combined administration of catalase deriva-
tives and cisplatin increased the survival of tumor-bearing
mice (Figure 5c and d). Although the antitumor activity of
cisplatin depends on its direct interaction with DNA,
primarily by nucleotide excision repair,29 it also damages
the genetic material via generated ROS.3,4 Solid tumor tissues
are generally under hypoxic conditions, and tumor cells
contain a greatly reduced number of mitochondria and
they rely mostly on glycolysis for energy.30 These conditions
will lead to a reduced production of ROS within tumor
tissues, so the cisplatin-induced oxidative damage would
affect tumor tissues to a lesser degree than normal tissues,
such as kidneys.
In addition to its cytotoxicity due to its oxidative activity,
hydrogen peroxide acts as a second messenger that influences
the expression of a number of genes and signal transduction
pathways.31 In fact, sublethal concentrations of hydrogen
peroxide are reported to stimulate cell proliferation.32,33 The
administration of ED-catalase to cisplatin-treated B16-BL6-
bearing mice tended to reduce the number of tumor cells
determined at day 21 (Figure 5a), although the difference
compared with saline-treated mice was not statistically
significant: 5.372.1 106 cells and 1.471.0 106 cells for
the saline- and the ED-catalase-treated mice, respectively.
These results suggest that the proliferation of B16-BL6 cells in
subcutaneous tumor tissues is inhibited to some extent by
ED-catalase, which is in good agreement with previous
reports demonstrating that cell proliferation is inhibited by
co-expression of catalase.34 We have recently reported that
metastatic tumor growth aggravated by tumor removal is
significantly inhibited by polyethyleneglycol-conjugated cat-
alase.20 Furthermore, in a series of studies, we have shown
that the administration of catalase derivatives is highly
effective in inhibiting experimental tumor metastasis to the
liver,15 lung,18–20 and peritoneal organs.21 Various processes,
including the very early steps of tumor metastasis, such as
adhesion of tumor cells to the endothelium, were inhibited
by catalase derivatives.19 We have recently reported that i.p.
ED-catalase is effective in inhibiting experimental peritoneal
dissemination of murine carcinoma cells in mice.35,36 These
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Figure 5 | Effect of catalase and ED-catalase on the antitumor
activity of cisplatin in tumor-bearing mice. (a) B16-BL6/Luc
(5 105) or (b) S180 (2.5 105) was inoculated subcutaneously into
mice, and at 7 days after inoculation mice received three injections of
5 mg cisplatin per kg into the peritoneal cavity at 24-h intervals.
Catalase or ED-conjugated catalase (10 000 U kg1 shot1) was
injected into the tail vein of mice at 12 h before the first injection of
cisplatin. The second shot was administered to mice immediately
after the first injection of cisplatin, and three additional doses were
administered at 24-h intervals. (a) On day 21, B16-BL6/Luc-bearing
mice were euthanized and the luciferase activity of the tumor tissues
was measured. UT, untreated; Cat, catalase; ED-cat, ED-catalase.
Results are expressed as the mean7s.d. of five mice. (b) The
dimensions of the subcutaneous S180 tumor tissues were measured
every other day and the tumor volume was estimated. (K),
untreated; (J), cisplatin-injected, saline-treated; (&) cisplatin-
injected, catalase-treated; (n) cisplatin-injected, ED-catalase-treated.
Results are expressed as the mean7s.d. of 12 mice. (c, d) Survival of
tumor-bearing mice. Groups of 12 B16-BL6 (c)- and S180 (d)-bearing
mice were treated as described above. Differences in the survival of
mice were significantly different between (c) saline and catalase
(Po0.05), saline and ED-catalase (Po0.001), and catalase and
ED-catalase (Po0.01) and (d) saline and ED-catalase (Po0.01).
In both cases, no significant differences were obtained between the
untreated and the saline-treated groups (P¼ 0.48 and 0.17,
respectively). (e, f) Survival of tumor-bearing mice that escaped
cisplatin-induced acute death. The survivors for the first 37 (e) and 42
days (f) in the experiments shown in (c and d) are plotted.
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pieces of evidence suggest that not only the proliferation of
tumor cells but also their metastasis is inhibited by catalase
derivatives.
The survival data on mice that escaped cisplatin-induced
acute death showed that ED-catalase can increase the
survival of B16-BL6- or S180-bearing mice, with a greater
effect in B16-BL6-bearing animals. The difference in the
metastatic ability of these two cell lines (B16-BL6 is a highly
metastatic clone) would explain the differences in the survival
rates of the tumor-bearing mice treated with ED-catalase.
Further studies are needed to confirm how catalase
derivatives affect the proliferative and metastatic nature of
tumor cells.
In conclusion, this study has demonstrated that cationiza-
tion of catalase is an efficient method for targeting the
antioxidant enzyme to renal tubule cells, thereby protecting
against the renal dysfunction induced by cisplatin. The
cationized catalase, ED-catalase, does not interfere with the
antitumor activity of cisplatin, but significantly prevents
drug-induced acute death, resulting in an increased survival
of tumor-bearing mice treated with cisplatin.
MATERIALS AND METHODS
Chemicals
Cisplatin was obtained from Nippon Kayaku Co. (Tokyo, Japan).
Bovine liver catalase (EC 1.11.1.6) and 1-ethyl-3-[3-(dimethylami-
no)propyl] carbodiimide hydrochloride were purchased from Sigma
Chemical (St Louis, MO, USA). ED was obtained from Wako Pure
Chemical Industries Ltd (Osaka, Japan). Dulbecco’s modified Eagle’s
minimum essential medium and Hank’s buffered salt solution were
obtained from Nissui Pharmaceutical (Tokyo, Japan). Fetal bovine
serum was obtained from Biowhittaker (Walkersville, MD, USA).
All other chemicals were of analytical grade.
Animals
Male ddY mice (4- to 5-week-old) and male C57BL/6 mice (6-week-
old) were purchased from the Shizuoka Agricultural Cooperative
Association for Laboratory Animals (Shizuoka, Japan). Animals
were maintained under conventional housing conditions. The
protocols for animal experiments were approved by the Animal
Experimentation Committee of the Graduate School of Pharma-
ceutical Sciences of Kyoto University.
Synthesis and characterization of ED-catalase
The coupling of ED to catalase was performed as described
previously.14 The number of increased free amino groups of ED-
catalase was 13.6, and its remaining enzymatic activity was about
44%. This reduction in enzymatic activity would be mainly due to
changes in the structure of catalase by the coupling of ED.14
Immunohistochemical staining of catalase derivatives in
kidney sections
Kidneys were collected from mice 30 min after intravenous injection
of catalase or ED-catalase at a dose of 1 mg kg1. Then, the kidneys
were fixed using an acetone–methylbenzoate–xylene method, and
paraffin-embedded sections were prepared. Sections were also made
by collecting kidneys after injection of catalase at a high dose of
100 mg kg1, and these sections were used as a positive control for
the immunohistochemical staining of bovine liver catalase. The
sections were immunostained for bovine catalase using a 1:500
dilution of antibovine catalase rabbit antibody (Rockland, Gilberts-
ville, PA, USA), followed by incubation with peroxidase-labeled
secondary antibody (Histofine Simplestain Max PO; Nichirei,
Tokyo, Japan). The sections were then incubated with 3,30-
diaminobenzidine tetrahydrochloride substrate solution to allow
development of a brown color.
Measurement of renal catalase activity
Kidneys were collected from mice 30 min after intravenous injection
of catalase or ED-catalase at a dose of 1 mg kg1. Then, the kidneys
were homogenized with a lysis buffer (0.05% Triton X-100, 2 mM
ethylenediaminetetraacetic acid, 0.1 M Tris (pH 7.8)). Catalase
activity in the supernatant of tissue homogenates was measured
using an Amplexs Red Catalase Assay Kit (Molecular Probes Inc.,
Eugene, OR, USA).
Nephrotoxicity of single-dose cisplatin and its inhibition
by catalase derivatives
Groups of 4–6 mice received i.p. injections of 20 mg kg1
cisplatin. Catalase (5000–50 000 U kg1 shot1) or ED-catalase
(10 000 U kg1 shot1) was injected into the tail vein of mice twice
a day, beginning 12 h before the cisplatin injection and this was
continued for seven doses at 12-h intervals. The dosing schedule of
catalase derivatives was determined based on previous reports in
which attempts were made to inhibit cisplatin-induced nephrotoxi-
city.37,38 The saline-treated (control) group received an intravenous
injection of an isotonic saline solution. Animals were euthanized
3 days (72 h) after the cisplatin injection.
Nephrotoxicity of repeated doses of cisplatin and its
inhibition by catalase derivatives
Groups of 5–8 mice received three injections of 5 mg cisplatin per kg
into the peritoneal cavity on days 0, 1, and 2 at 24-h intervals.
Catalase or ED-catalase (10 000 U kg1) was injected into the tail
vein of mice 12 h before the cisplatin injection. Then, the second
injection was given immediately after the first injection of cisplatin,
and three additional doses were administered at 24-h intervals.
Again, isotonic saline solution was given intravenously to the saline-
treated (control) group instead of catalase derivatives. Animals were
euthanized 4 days (96 h) after the first cisplatin injection.
Biochemical parameters of nephropathy
At indicated periods after treatments, mice were euthanized, blood
was collected from the vena cava, and serum was separated by
centrifugation for 20 min at 3000 g, 41C. Serum LDH activity and
the nitrite/nitrate level were determined using the Lactate Dehy-
drogenase C-II Test Wako (Wako Pure Chemical Co.) and the NO2/
NO3 Assay Kit-C II (Dojindo Molecular Technologies Inc.,
Kumamoto, Japan), respectively. The kidneys were isolated, washed
with saline, and weighed. Part of the kidney samples was
homogenized in 5% sulfosalicylic acid and the total GSH content
measured39 using an assay kit (Total Glutathione Quantification Kit,
Dojindo Molecular Technologies Inc.). The remaining part of the
kidney was used to measure the MDA level by the method of
Wasowicz et al.40 based on the reaction of MDA with thiobarbituric
acid at 95–1001C. The fluorescence intensity of MDA in the upper
n-butanol phase was measured in a fluorescence spectrophotometer
(Wallac 1420 ARVOMX Multilabel Counter, Perkin-Elmer, Finland)
with excitation at 530 nm and emission at 560 nm. Arbitrary values
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obtained were compared with a series of standard solutions
of 1,1,3,3-tetramethoxypropane. Renal damage was assessed by
monitoring serum levels of BUN and creatinine. The BUN and
creatinine levels were measured by the diacetylmonoxime method41
and Jaffe’s method,42 respectively, using assay kits purchased from
Wako Pure Chemical Co. (Urea NB Test Wako and Creatinine Test
Wako, respectively).
Histological evaluation of nephrotoxicity
At 72 h after injection of cisplatin at a dose of 20 mg kg1, kidneys
were isolated from mice, fixed in 4% paraformaldehyde, dehydrated,
and embedded in 70% ethanol. Then, 3 mm tissue sections were
prepared, stained with hematoxylin and eosin, and examined for
tubular necrosis and dilatation. The slides were coded, and a
semiquantitative analysis of the sections was performed without
knowledge of the treatment protocol, as described previously.38 The
changes observed were limited to the tubulointerstitial areas and
graded as follows: 0, normal; I, areas of tubular epithelial cell
swelling, vacuolar degeneration, necrosis, and desquamation invol-
ving o25% of the cortical tubules; II, similar changes involving
425% but o50% of the cortical tubules; III, similar changes
involving 450% but o75% of the cortical tubules; IV, similar
changes involving 475% of the cortical tubules.
Measurement of platinum contents in kidneys
Groups of 3–4 mice were treated as described above with cisplatin (a
single injection of 20 mg kg1 or three injections of 5 mg kg1) and
ED-catalase (seven doses of 10 000 U kg1 or five doses of
10 000 U kg1, respectively). At 24 h after the last injection of ED-
catalase, mice were euthanized and kidneys were harvested and
homogenized in distilled water. Then, the tissue homogenates were
centrifuged at 250 g for 10 min and the supernatant was collected for
the measurement of platinum concentration by atomic absorption.
Tumor cells
Murine melanoma B16-BL643 and B16-BL6/Luc19 cells were grown
in Dulbecco’s modified Eagle’s minimum essential medium
supplemented with 10% heat-inactivated fetal bovine serum,
0.15% sodium bicarbonate, 100 U ml1 penicillin and 100 mg ml1
streptomycin, at 371C under an atmosphere of 5% CO2 in air. Then,
5 105 cells were suspended in Hank’s buffered salt solution and
inoculated subcutaneously into mice. Separately, murine sarcoma
180 (S180) was maintained in ddY mice by weekly i.p. transfer of
2.5 105 cells. S180 cells (1 106) were inoculated subcutaneously
to obtain tumor-bearing mice.
Effects of catalase derivatives on the antitumor activity of
cisplatin
At 7 days after tumor inoculation, groups of 12 mice began to
receive three injections of 5 mg cisplatin per kg into the peritoneal
cavity at 24-h intervals. Catalase or ED-catalase (10 000 U kg1) was
injected according to the same protocol as used for the repeated
doses of cisplatin as described above. The dimensions of the
subcutaneous S180 tumor tissues were measured with a caliper every
other day, and the tumor volume was estimated from the following
equation: volume¼ 1/2LW2, where L is the long diameter and W is
the short diameter of the tissue. Then, survival of S-180- or B16-
BL6-bearing mice was evaluated. In different sets of mice, B16-BL6/
Luc-bearing mice (n¼ 5 animals per group) were euthanized on day
21, and the luciferase activity of tumor tissues was measured using a
luminometer (Lumat LB 9507, EG & G Berthold, Bad Wildbad,
Germany) as reported previously.19
Statistical analysis
Differences were statistically evaluated by one-way analysis of
variance followed by the Fisher PLSD multiple comparison text,
and Kaplan–Meier analysis with a log-rank test to determine
survival. The level of statistical significance was set at Po0.05.
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